Treace Medical Concepts, Inc. (TMCI) Cash Flow Statement

The gap is directionally favorable in the accounting sense — cash losses run materially smaller than book losses — but it should not be read as evidence of an approaching breakeven. Roughly $71M of disclosed stock-based compensation over the period accounts for the majority of the $98M reconciliation, meaning the divergence reflects dilution rather than cash economics. Investors should note that the cash side of the business is still consuming capital; the cumulative -$50.5M operating outflow simply understates the true economic cost of the reported deficit.

The two positive FCF quarters both coincided with large favorable working capital swings (+$7.7M and +$14.7M respectively), while the intervening quarters reverted to negative FCF averaging roughly -$10M. This pattern suggests the underlying cash trajectory has not improved in step with the revenue story described in the income statement. The most recent quarter, 2026Q2, printed -$6.9M of FCF at a -15.2% margin, which appears to indicate that the burn resumes as soon as the working capital tailwind laps.

The recurring fourth-quarter reversals (-$17.0M in 2024Q4, -$13.1M in 2025Q4) alongside first-quarter releases appear consistent with seasonality in order timing, echoing the prior finding that calendar-driven ordering may underlie reported results. That cyclicality makes single-quarter OCF prints particularly unreliable as a signal, and 2026Q2's +$1.1M contribution was too small to offset the -$4.7M operating outflow. Analysts should monitor whether receivables and inventory builds intensify as revenue contracts, since a shrinking top line with lagging working capital releases could pressure cash further.

In most loss-making quarters the ratio sits between 0.3 and 0.9, implying cash outflow roughly proportional to the book loss; the outlier quarters (2024Q4 at 8.40 and 2026Q1 at -0.40) are artifacts of working capital timing rather than conversion quality. The negative ratio in 2026Q1 is notable because the company generated positive OCF on a deeply negative net income, which typically signals aggressive collections or inventory liquidation. The absence of a stable conversion band means accrual-based earnings quality assessment is of limited use here, and cash flow must be evaluated on its own trajectory.

Because depreciation broadly approximates capex in most quarters, the maintenance requirement appears modest and the company is not layering heavy capacity investment on top of operating losses — a relative positive versus capital-intensive device peers. However, capex of $30.4M cumulative against -$80.8M of cumulative FCF means even eliminating all capital spending would not have produced breakeven cash flow over the period. The occasional spikes (10.1% of revenue in 2025Q2, 7.7% in 2024Q1) warrant monitoring to determine whether they represent discretionary growth investment or recurring tooling and equipment needs tied to the surgical platform.